Richard Davies Appointed Chief Executive Officer Of Auregen BioTherapeutics

Mr. Davies brings over 27 years of Life Sciences industry experience to Auregen BioTherapeutics, a pioneering 3D bioprinting company developing innovative treatments for patients with rare disorders.

Geneva, Switzerland, November 20th 2018 … Auregen BioTherapeutics today announced the appointment of Richard Davies as CEO.

Auregen BioTherapeutics is a rare disease cell therapy company, applying innovative 3D biofabrication technologies to tissue engineering and regenerative medicine. Auregen is headquartered in Geneva, Switzerland, with facilities in Zurich and a USA subsidiary based in Cambridge, Massachusetts. Auregen’s lead investor is Gurnet Point Capital.

Auregen is pioneering 3D bioprinting through an intellectual property platform which includes exclusive licenses from academic institutions, such as the Swiss Federal Institute of Technology in Zurich (ETH Zurich). The company’s initial clinical focus is to create new treatment options for patients with rare congenital craniofacial disorders.

Richard Davies previously spent three years as CEO of Bonesupport AB. During his tenure, he secured a crossover financing, which enabled an initial public offering of the company in June of last year. Under his leadership, Bonesupport increased sales by over 50% and initiated its pivotal US PMA study for Cerament Gentamycin. Mr. Davies was awarded European Medtec CEO of the year for 2017.

Prior to Bonesupport AB, Mr. Davies served as Chief Commercial Officer of Hospira Inc., a global pharmaceutical company. While at Hospira, he drove company-wide growth, globalisation and modernisation for nearly a half decade. Hospira was acquired by Pfizer in 2015 for $17B.

Earlier in his career, Mr. Davies spent nine years in increasingly senior leadership positions at Amgen including global positions within Europe, Australia and the U.S. His roles while at Amgen encompassed initiation of clinical and commercial operations in Europe, leadership of the company’s Australia and New Zealand businesses, and leadership of the inflammation commercial franchise within the U.S. Mr. Davies also led Amgen’s business units in Latin America and Asia. He began his pharmaceutical career at Eli Lilly and holds a Bachelor’s degree in Applied Chemistry from Portsmouth University and an MBA from Warwick Business School.
Travis Wilson, a Partner at Gurnet Point Capital and the Chairman of Auregen commented:

“Auregen BioTherapeutics has reached an inflection with its lead rare disease program transitioning to the clinic. Our aim of helping patients with craniofacial disorders for which there are few treatment alternatives is coming into focus. With this patient-driven mission, there is a need for a deeply experienced CEO with a proven track record to develop and commercialise novel therapies for unmet medical needs. In Richard, we more than have that person and he broadens our ability to impact the lives of patients. I’m delighted to welcome Richard to the company and look forward to working together at this important juncture for Auregen and for the patients our technology will serve.”

Richard Davies commented:

“I am delighted to be joining Auregen BioTherapeutics as CEO as we embark on this next important part of its journey towards treating patients. Auregen is developing a remarkable technology which will lead to breakthrough therapies across a spectrum of rare diseases. Our task now is to make Auregen a leader in cell therapy, translating its technology into registered therapeutics for the benefit of patients and driving the expansion of the company’s pipeline.”

--ENDS--

About Gurnet Point Capital

Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Christopher Viehbacher who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of $2 billion, Gurnet Point Capital is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge MA, USA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialization and does so with an approach that is a hybrid of venture and private equity investing strategies. www.gurnetpointcapital.com